Figure 1. Patient Enrollment and Treatment Assignment of the BLAZE-1 Trial of Bamlanivimab for Mild to Moderate COVID-19.

SARS-CoV-2 indicates severe acute respiratory syndrome coronavirus 2.

^aStratified by duration since symptom onset to randomization (≤8 days vs >8 days).

^bIncluded in the adverse event analysis.

^cHad data on at least 1 postbaseline viral load.

^dThree patients were excluded from the efficacy analysis because they did not have data on at least 1 postbaseline viral load. However, these patients were included in the safety analysis because they did receive the intervention as randomized.

^eFour patients were excluded from the efficacy analysis because they did not have data on at least 1 postbaseline viral load. However, these patients were included in the safety analysis because they did receive the intervention as randomized.

^fHad data on viral load for both baseline and at day 11.